Abstract: The present invention relates to a method and system for neuropsychological performance test, comprising A terminal device (101), used to interact with a cloud server (102) which stores user information and is logged into by user through the terminal device (101); the user information obtained by the terminal device (101) are input and stored to the cloud server (102) in a login state; a test module (400) comprises the user information, which is stored in the cloud server (102) or can be downloaded from the cloud server (102), and is directly accessed through said terminal device (101) and is trained by artificial neural network; and said user information comprises user biometrics or emotions identification information, neuropsychological performance test answers information, and user latency or user chronometrics information; and said terminal device (101) displays neuropsychological performance test results.

Abstract: The present invention relates to a method and system of cybersecurity; and particularly relates to an encryption method and system on the basis of cognitive computing for xenomorphic cryptography or unusual form of cryptography; said method comprises generating a Functional Neural Network or KeyNode (KN) of the system by programming a chain of multiple nodes also called Artificial Mirror Neurons (AMN) based on captured information of reaction time and emotional response to a simple task; racing the nodes in the Functional Neural Network or KeyNode (KN) as an encryption device or cipher for the time of use; generating a password at the time of use based on the sum of intrinsic values of the nodes in the racing network at this time and adopting the generated password for authentication.

Abstract: A travelling-wave tube comprising a helix joined by posts to a vacuum chamber, each post made of electrically insulating material being covered by an electrically conductive material, of electrical conductivity comprised between 1000 and 100000 S·m?1, over a portion of the post extending from the end of the post joined to the helix to the end of the post joined to the vacuum chamber and corresponding to a height comprised between 10% and 50% of the post.

Abstract: The present invention discloses compounds according to Formula I: Wherein R1, R2, R3a, R3b, and Cy are as defined herein. The present invention relates to compounds inhibiting ADAMTS, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of inflammatory conditions, and/or diseases involving degradation of cartilage and/or disruption of cartilage homeostasis by administering a compound of the invention.

Abstract: The present invention is directed to a method for identifying a gene that regulates clostridial neurotoxin activity, the method comprising: a. providing a sample of human neuronal cells expressing a polypeptide that comprises a C-terminal detectable label, wherein the polypeptide is cleavable by a clostridial neurotoxin; b. altering expression of a target gene of the cells; c. contacting the cells with the clostridial neurotoxin; d. measuring an amount of C-terminal detectable label, thereby quantifying clostridial neurotoxin activity; and e. identifying the target gene as a regulator of clostridial neurotoxin activity when the quantified clostridial neurotoxin activity is different to the quantified clostridial neurotoxin activity when expression of the target gene is unaltered; or f.

Abstract: A travelling-wave tube comprising a helix joined by posts to a vacuum chamber, each post made of electrically insulating material being covered by an electrically conductive material, of electrical conductivity comprised between 1000 and 100000 S·m?1, over a portion of the post extending from the end of the post joined to the helix to the end of the post joined to the vacuum chamber and corresponding to a height comprised between 10% and 50% of the post.

Abstract: The present invention discloses compounds according to Formula I: Wherein R1, R2, R3a, R3b, and Cy are as defined herein. The present invention relates to compounds inhibiting ADAMTS, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of inflammatory conditions, and/or diseases involving degradation of cartilage and/or disruption of cartilage homeostasis by administering a compound of the invention.

Abstract: The present invention discloses compounds according to Formula I: Wherein R1, R2, R3a, R3b, and Cy are as defined herein. The present invention relates to compounds inhibiting ADAMTS, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of inflammatory conditions, and/or diseases involving degradation of cartilage and/or disruption of cartilage homeostasis by administering a compound of the invention.

Abstract: The present invention discloses compounds according to Formula I: Wherein R1, R2, R3a, R3b, R6a, R6b, the subscript n and Cy are as defined herein. The present invention relates to compounds inhibiting ADAMTS, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of inflammatory diseases, and/or diseases involving degradation of cartilage and/or disruption of cartilage homeostasis by administering the compound of the invention.

Abstract: The present invention discloses compounds according to Formula I: Wherein R1, R2, R3a, R3b, and Cy are as defined herein. The present invention relates to compounds inhibiting ADAMTS, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of inflammatory conditions, and/or diseases involving degradation of cartilage and/or disruption of cartilage homeostasis by administering a compound of the invention.

Abstract: The present invention discloses compounds according to Formula I: Wherein R1, R2, R3a, R3b, R6, Cy, and the subscript n are as defined herein. The present invention relates to compounds inhibiting ADAMTS, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of inflammatory diseases, and/or diseases involving degradation of cartilage and/or disruption of cartilage homeostasis by administering the compound of the invention.

Abstract: A cell stack comprising an electrochemical cell, or a plurality of axially arranged electrochemical cells, with an end plate at each end of the stack, each cell comprising an active area surrounded by a peripheral area, wherein the active area comprises the membrane electrode assembly, and the peripheral area includes one or more channels for reactants, and wherein the stack comprises means for applying pressure axially to the active area to contact the membrane and electrodes, and separate means for applying pressure axially to the peripheral area. Further, a method of performing an electrochemical reaction in a cell comprising an active area surrounded by a peripheral area, comprises applying pressure to the active area, and varying the pressure during operation of the cell, wherein the active area includes the membrane electrode assembly and is the area where the cell reaction occurs.

Abstract: The present invention discloses compounds according to Formula I: Wherein R1, R2, R3a, R3b, and Cy are as defined herein. The present invention relates to compounds inhibiting ADAMTS, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of inflammatory conditions, and/or diseases involving degradation of cartilage and/or disruption of cartilage homeostasis by administering a compound of the invention.

Abstract: The present invention discloses compounds according to Formula I: Wherein R1, R2, R3a, R3b, R6a, R6b, the subscript n and Cy are as defined herein. The present invention relates to compounds inhibiting ADAMTS, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of inflammatory diseases, and/or diseases involving degradation of cartilage and/or disruption of cartilage homeostasis by administering the compound of the invention.

Abstract: The present invention discloses compounds according to Formula I: Wherein R1, R2, R3a, R3b, R6, Cy, and the subscript n are as defined herein. The present invention relates to compounds inhibiting ADAMTS, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of inflammatory diseases, and/or diseases involving degradation of cartilage and/or disruption of cartilage homeostasis by administering the compound of the invention.

Abstract: A composite cell plate can include a polymer element laterally mated and interlocked, at a plurality of engagement points, with a resilient metal element. The cell plate can be used in an electrochemical cell. A method of forming a cell plate can include fitting a polymer element to a resilient metal element at a plurality of engagement points, and expanding the polymer of the polymer element such that the polymer element and the resilient metal element engage and interlock at the engagement points.

Abstract: Described herein are polypeptides comprising a lipoprotein export signal, polypeptide precursors comprising a lipoprotein export signal, nucleic acids encoding said polypeptides or polypeptide precursors, recombinant expression vectors comprising nucleic acids encoding said lipoprotein export signal and/or polypeptides or polypeptide precursors, and 5 recombinant host cells comprising these vectors. The application further provides uses of these polypeptides, polypeptide precursors, nucleic acids, recombinant expression vectors and recombinant host cells.

Abstract: A cell stack comprising an electrochemical cell, or a plurality of axially arranged electrochemical cells, with an end plate at each end of the stack, each cell comprising an active area surrounded by a peripheral area, wherein the active area comprises the membrane electrode assembly, and the peripheral area includes one or more channels for reactants, and wherein the stack comprises means for applying pressure axially to the active area to contact the membrane and electrodes, and separate means for applying pressure axially to the peripheral area. Further, a method of performing an electrochemical reaction in a cell comprising an active area surrounded by a peripheral area, comprises applying pressure to the active area, and varying the pressure during operation of the cell, wherein the active area includes the membrane electrode assembly and is the area where the cell reaction occurs.

Abstract: The present invention discloses compounds according to Formula I: Wherein R1, R2, R3a, R3b, and Cy are as defined herein. The present invention relates to compounds inhibiting ADAMTS, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of inflammatory conditions, and/or diseases involving degradation of cartilage and/or disruption of cartilage homeostasis by administering a compound of the invention.

Abstract: A cell stack comprising an electrochemical cell, or a plurality of axially arranged electrochemical cells, with an end plate at each end of the stack, each cell comprising an active area surrounded by a peripheral area, wherein the active area comprises the membrane electrode assembly, and the peripheral area includes one or more channels for reactants, and wherein the stack comprises means for applying pressure axially to the active area to contact the membrane and electrodes, and separate means for applying pressure axially to the peripheral area. Further, a method of performing an electrochemical reaction in a cell comprising an active area surrounded by a peripheral area, comprises applying pressure to the active area, and varying the pressure during operation of the cell, wherein the active area includes the membrane electrode assembly and is the area where the cell reaction occurs.